Giredestrant reduced the risk of disease progression or death by 44% compared with standard endocrine therapy plus everolimus in patients with ER-positive advanced breast cancer, according to phase III trial results published October 1 in The New England Journal of Medicine. The findings provide the clearest clinical evidence yet that an oral SERD paired with an mTOR inhibitor can outperform the longstanding backbone regimen of an aromatase inhibitor and everolimus.
Phase III evERA Trial Results and Progression-Free Survival
The evERA trial evaluated the efficacy and safety of giredestrant combined with everolimus against standard endocrine therapy paired with everolimus in a large, randomized patient population. The intent-to-treat analysis yielded a hazard ratio demonstrating a 44% improvement in progression-free survival for the giredestrant arm. Everolimus in combination with an aromatase inhibitor has served as a standard treatment option since receiving U.S. Food and Drug Administration approval in 2012. Historically, clinicians added the injectable SERD fulvestrant to that backbone as an incremental option for patients whose disease progressed on prior hormonal therapy. While giredestrant offers the practical advantage of being an oral medication that removes the burden of intramuscular injections, the primary clinical distinction in the evERA data rests on the separation of the progression-free survival curves.
Clinical Context and Regulatory Implications
Roche’s earlier phase II coopERA study demonstrated that giredestrant outperformed standard of care regarding anti-proliferative activity in early-stage disease, generating anticipation for the phase III readout. Publication in The New England Journal of Medicine places the complete dataset before regulatory bodies and payers simultaneously, bypassing conference abstract limitations. Regulators increasingly accept progression-free survival as a primary endpoint in ER-positive metastatic breast cancer. However, payer committees across multiple healthcare markets require overall survival data or strong patient-reported outcomes before committing to pricing that reflects a step-change over existing therapies. The forthcoming overall survival readout from the evERA trial will determine whether giredestrant secures a label position ahead of current standard therapies.
Giredestrant oral SERD reduces disease progression risk
What is giredestrant?
Giredestrant is an oral SERD.
How does the evERA trial compare giredestrant to standard care?
The trial paired giredestrant with everolimus and compared patient outcomes against standard endocrine therapy combined with everolimus, showing a 44% reduction in the risk of disease progression or death.
Why is an oral SERD significant for patients?
An oral medication eliminates the need for intramuscular injections, which are required for fulvestrant, though clinical evaluation focuses primarily on progression-free survival benefits.
Related reading